| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 17.00 - 18.00 | Registration/ Snack | ||
| 18.00 - 18.10 | Welcome to CtS | ||
| 18.10 - 18.50 | Factors affecting response to immunotherapy | TBA | |
| 18.50 - 19.25 | Antigen specific immunotherapies | TBA | |
| 19.25 20.00 | How to deal with increasing drug related costs | TBA | |
| 20.00 | Diner |
| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 9.00 - 9.20 | Controverses in melanoma pathology | Antien Mooyaart | Erasmus MC |
| 9.20 - 9.50 | Update in UV induced carcinogenesis / tumor immunology | TBA | |
| 9.50 - 10.20 | Adjuvant immunotherapy in melanoma | Carolien Robert | Gustave-Roussy |
| 10.20 - 10.40 | Impact of 8th AJCC on melanoma outcomes | Max Madu | UMCG |
| 10.40 - 11.00 | Coffee Break | ||
| 11.00 - 11.30 | New Dutch CSCC guideline | TBA | |
| 11.30 - 11.50 | Micrographic Mohs surgery for CSCC | Renate van den Bos | Erasmus MC |
| 11.50 - 12.10 | Isolated limb perfusion in CSCC | TBA | |
| 12.10 - 12.30 | Anti-PD1 treatment in advanced CSCC | Dirk Schadendorf | University Hospital Essen |
| 12.30-14.00 | Lunch | ||
| 14.00 - 14.20 | Sentinel node procedure for head and neck skin cancer? | TBA | |
| 14.20 - 14.50 | Prognosis of Merkel cell carcinoma | TBA | |
| 14.50 - 15.10 | Avelumab for Merkel cell carcinoma | Hilde Jalving | UMCG |
| 15.10 - 15.40 | Pro Contra debate Adjuvante TT vs. adjuvante IO voor BRAF+ stadium III melanoom melanoom | TBA | |
| 15.40 - 16.10 | Coffee Break | ||
| 16.10 - 16.40 | Triple therapy in melanoma: more is better? | James Larkin | Royal Marsden Hospital |
| 16.40 - 17.00 | Melanoma treatment in immunocompromised patients | Astrid vd Veldt? | Erasmus MC |
| 17.00- 17.20 | Locoregional therapy vs. systemic therapy for in transit metastasis | TBA | |
| 17.20 - 17.40 | Treatment of brain mets | TBA | |
| 17.40 -18.00 | Organisation of melanoma care (in The Netherlands) | TBA | |
| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 8.45 - 9.05 | Melanoma mortality: the Breslow paradox | Loes Hollestein | Erasmus MC |
| 9.05 - 9.35 | What to do with stage II melanoma? | Lex Eggermont | Gustave-Roussy |
| 9.35 - 9.55 | Risk of melanoma in lentigo maligna | Judith Zoutendijk | Erasmus MC |
| 9.55 - 10.15 | Skin cancer mortality in transplant recipients | TBA | |
| 10.15 - 10.45 | Coffee Break | ||
| 10.45 - 11.05 | Comparative RCT of topical AK therapies: 1 year results. | Maud Jansen | MUMC |
| 11.05 - 11.25 | Skin cancer costs in The Netherlands | Eline Noels | Erasmus MC |
| 11.25 - 11.45 | Basal cell carcinoma; genetics and clinical implications | Klara Mosterd | MUMC |
| 11.45 - 12.10 | Views & opinions of skin cancer patients and health care providers | TBA | |
| 12.10 - 12.30 | Aggressive adnexal tumors of the skin | TBA | |
| 12.30 - 13.30 | Lunch | ||
| 13.30 - 13.50 | Prognostic factors of CSCC progression: UK perspective. | Tamar Nijsten | Erasmus MC |
| 13.50 - 14.20 | How to deal with advanced keratinocytic cancers? | Alexander Stratigos | A. Sygros Hospital, Athene |
| 14.20 - 14.40 | The expansion of Mohs micrographic surgery in The Netherlands | TBA | |
| 14.40 - 15.10 | Tips & tricks of complex reconstruction in head and neck region. | TBA | |
| 15.10 - 15.15 | Closure of Cells to Surgery 2019 | ||
